Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03055897 · ClinicalTrials.gov registry record · NA

Tear Film Innovations iLux Safety Study

A NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye, sponsored by Tear Film Innovations.

Completed
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT03055897 is a NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye that has completed, run by Tear Film Innovations. The registered enrollment target is 15 participants, below the 101-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03055897, a NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye, has completed, sponsored by Tear Film Innovations.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The objective of this study was to measure the temperature of the cornea and surrounding eye tissue temperature immediately after heating the eyelids with the iLux device using the protocol treatment profile. Eligible participants attended one treatment visit, with follow-up one day following the procedure.

Interventions

  • DEVICE iLux 2020 System

Study Locations (1)

California

  • TearFilm Innovations Investigative Site - Encinitas

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2016-05-03
Est. Completion 2016-05-18
Phase NA

Sponsor

Tear Film Innovations

3 total trials

What the Registry Record Tells You About NCT03055897

The ClinicalTrials.gov registry entry for NCT03055897 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (85% lower). The listed sponsor is Tear Film Innovations, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Meibomian Gland Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which iLux 2020 System is the first listed.

NCT03055897 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03055897 about?

NCT03055897 is a clinical study titled "Tear Film Innovations iLux Safety Study". The objective of this study was to measure the temperature of the cornea and surrounding eye tissue temperature immediately after heating the eyelids with the iLux device using the protocol treatment profile. Eligible participants attended one treatment visit, with follow-up one day following the pr...

What is the current status of trial NCT03055897?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2016-05-03. Estimated completion is 2016-05-18.

What conditions does trial NCT03055897 study?

This clinical trial studies the following conditions: Meibomian Gland Dysfunction, Evaporative Dry Eye.

What interventions are being tested in trial NCT03055897?

The interventions under investigation include: iLux 2020 System (DEVICE).

Who is sponsoring clinical trial NCT03055897?

This trial is sponsored by Tear Film Innovations, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03055897 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Meibomian Gland Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.